Patent application number | Description | Published |
20100049444 | CALIBRATION SURFACE METHOD FOR DETERMINATION OF ANALYTE RATIOS - The ratio of analytes is determined directly from the responses of the analytes using a conversion method. Individual analyte responses are obtained by using a selected measuring technique, and these individual responses are used as the independent variables in a conversion method. The dependent variable of conversion method is the desired analyte ratio. The resulting conversion method is then used to directly calculate the desired ratio of analytes as a function of the measured responses. No intermediate conversions, such as using a calibration curve to convert individual measured analyte responses to concentration values, are needed to obtain the desired ratio. | 02-25-2010 |
20110117670 | MULTIPLEX IMMUNOASSAYS FOR HEMOGLOBIN, HEMOGLOBIN VARIANTS, AND GLYCATED FORMS - Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided. | 05-19-2011 |
20120084010 | Dose Surface Method for Determination of Analyte Ratios - Methods, systems, and apparatus for accurately determining a proportion (ratio) of two analytes is provided, as well as provide a concentration of a first analyte from a determined concentration of a second analyte and from a proportion of the analytes to each other. In one aspect, a surface model (called a “dose surface” herein) relating the concentrations of the two analytes to the proportion can be used to obtain accurate values for one of the variables (e.g. a concentration or the proportion) when the other two variables have previously been obtained. The dose surface can be a three-dimensional surface and be non-linear. The dose surface model can include multiple regression functions. For example, measured responses can be individually converted to concentrations using two dose-response curves, and the concentrations can be input to a dose surface function to obtain the proportion. | 04-05-2012 |
20130288274 | RECOMBINANT DEAMIDATED GLIADIN ANTIGEN - The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a hexamer of a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing the gliadin fusion protein on the solid support. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase. | 10-31-2013 |
20140065634 | CHIMERIC ANTI-dsDNA/CHROMATIN ANTIBODY - Provided herein are antibodies for determining the concentration of anti-dsDNA and anti-chromatin antibodies in biological samples. | 03-06-2014 |
20140073532 | MULTIPLEX IMMUNOASSAYS FOR HEMOGLOBIN, HEMOGLOBIN VARIANTS, AND GLYCATED FORMS - Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided. | 03-13-2014 |
20140323332 | MULTIPLEX HEPATITIS B ASSAY - Provided herein are multiplex assays for determining whether an individual is or has been infected with Hepatitis B virus, and the stage of infection or resolution. In addition, the multiplex system can discriminate between vaccinated subjects and subjects susceptible to Hepatitis B infection. | 10-30-2014 |
20160068594 | MULTIPLEX IMMUNOASSAYS FOR HEMOGLOBIN, HEMOGLOBIN VARIANTS, AND GLYCATED FORMS - Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided. | 03-10-2016 |